Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Lin WL, Nguyen THY, Wu LM, Huang WT, Su SB. Anticancer Therapy and Mortality of Adult Patients with Hematologic Malignancy and COVID-19: A Systematic Review and Meta-Analysis. Life (Basel) 2023;13:life13020381. [PMID: 36836738 PMCID: PMC9967921 DOI: 10.3390/life13020381] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Revised: 01/15/2023] [Accepted: 01/17/2023] [Indexed: 01/31/2023] Open

For:	Lin WL, Nguyen THY, Wu LM, Huang WT, Su SB. Anticancer Therapy and Mortality of Adult Patients with Hematologic Malignancy and COVID-19: A Systematic Review and Meta-Analysis. Life (Basel) 2023;13:life13020381. [PMID: 36836738 PMCID: PMC9967921 DOI: 10.3390/life13020381] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Revised: 01/15/2023] [Accepted: 01/17/2023] [Indexed: 01/31/2023] Open

Number

Cited by Other Article(s)

Martínez-López J, de la Cruz J, Gil-Manso R, Yuste VJ, Aspa-Cilleruelo JM, Escobar CE, López-Jiménez J, Duarte R, Yerovi CJ, Hernández-Rivas JÁ, Herráez R, Quiroz-Cervantes K, Bustelos-Rodriguez R, Benavente C, Martínez Barranco P, Bastos Oteiro M, Alegre A, Pérez-Oteyza J, Ruiz E, Marcheco-Pupo EA, Cedillo Á, de Soto Álvarez T, García Ramirez P, Alonso Trillo R, Herrera P, Bengochea Casado ML, Arroyo Barea A, Martin De Bustamante JM, Ortiz J, Calbacho Robles M, García-Suárez J. COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant. Cancers (Basel) 2024;16:379. [PMID: 38254867 PMCID: PMC10814951 DOI: 10.3390/cancers16020379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Revised: 01/02/2024] [Accepted: 01/06/2024] [Indexed: 01/24/2024] Open

Abstract

A greater understanding of clinical trends in COVID-19 outcomes among patients with hematologic malignancies (HM) over the course of the pandemic, particularly the Omicron era, is needed. This ongoing, observational, and registry-based study with prospective data collection evaluated COVID-19 clinical severity and mortality in 1818 adult HM patients diagnosed with COVID-19 between 27 February 2020 and 1 October 2022, at 31 centers in the Madrid region of Spain. Of these, 1281 (70.5%) and 537 (29.5%) were reported in the pre-Omicron and Omicron periods, respectively. Overall, patients aged ≥70 years (odds ratio 2.16, 95% CI 1.64-2.87), with >1 comorbidity (2.44, 1.85-3.21), or with an underlying HM of chronic lymphocytic leukemia (1.64, 1.19-2.27), had greater odds of severe/critical COVID-19; odds were lower during the Omicron BA.1/BA.2 (0.28, 0.2-0.37) or BA.4/BA.5 (0.13, 0.08-0.19) periods and among patients vaccinated with one or two (0.51, 0.34-0.75) or three or four (0.22, 0.16-0.29) doses. The hospitalization rate (75.3% [963/1279], 35.7% [191/535]), rate of intensive care admission (30.0% [289/963], 14.7% [28/191]), and mortality rate overall (31.9% [409/1281], 9.9% [53/536]) and in hospitalized patients (41.3% [398/963], 22.0% [42/191]) decreased from the pre-Omicron to Omicron period. Age ≥70 years was the only factor associated with higher mortality risk in both the pre-Omicron (hazard ratio 2.57, 95% CI 2.03-3.25) and Omicron (3.19, 95% CI 1.59-6.42) periods. Receipt of prior stem cell transplantation, COVID-19 vaccination(s), and treatment with nirmatrelvir/ritonavir or remdesivir were associated with greater survival rates. In conclusion, COVID-19 mortality in HM patients has decreased considerably in the Omicron period; however, mortality in hospitalized HM patients remains high. Specific studies should be undertaken to test new treatments and preventive interventions in HM patients.

Collapse

Affiliation(s)

Joaquín Martínez-López Hematology Department, Hospital Universitario 12 de Octubre, imas12 Madrid, Universidad Complutense, CNIO-ISCIII, CIBERONC, 28041 Madrid, Spain; (R.G.-M.); (A.A.B.); (M.C.R.)
Javier de la Cruz imas12 Research Institute, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain;
Rodrigo Gil-Manso Hematology Department, Hospital Universitario 12 de Octubre, imas12 Madrid, Universidad Complutense, CNIO-ISCIII, CIBERONC, 28041 Madrid, Spain; (R.G.-M.); (A.A.B.); (M.C.R.)
Víctor Jiménez Yuste Hematology Department, Hospital Universitario La Paz, 28046 Madrid, Spain; (V.J.Y.); (T.d.S.Á.); (J.M.M.D.B.)
José María Aspa-Cilleruelo Hospital Universitario Príncipe de Asturias, Universidad de Alcalá, 28805 Madrid, Spain; (J.M.A.-C.); (P.G.R.); (J.G.-S.)
Cristian Escolano Escobar Hematology Department, Hospital Universitario de Getafe, 28905 Madrid, Spain; (C.E.E.); (R.A.T.)
Javier López-Jiménez Hematology Department, Hospital Universitario Ramón Y Cajal, 28034 Madrid, Spain; (J.L.-J.); (P.H.)
Rafael Duarte Hematology Department, Hospital Universitario Puerta de Hierro Majadahonda, 28222 Madrid, Spain;
Cristina Jacome Yerovi Hematology Department, Hospital Universitario Severo Ochoa, 28914 Madrid, Spain; (C.J.Y.); (M.L.B.C.)
José-Ángel Hernández-Rivas Hematology Department, Hospital Universitario Infanta Leonor, 28031 Madrid, Spain;
Regina Herráez Hematology Department, Hospital Universitario Infanta Sofía, 28702 Madrid, Spain;
Keina Quiroz-Cervantes Hematology Department, Hospital Universitario de Móstoles, 28935 Madrid, Spain;
Rosalía Bustelos-Rodriguez Hematology Department, Hospital Universitario del Sureste, 28500 Madrid, Spain;
Celina Benavente Hematology Department, Hospital Clínico San Carlos, 28040 Madrid, Spain;
Pilar Martínez Barranco Hematology Department, Hospital Universitario Fundación Alcorcón, 28922 Madrid, Spain;
Mariana Bastos Oteiro Hematology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, 28009 Madrid, Spain;
Adrián Alegre Hematology Department, Hospital Universitario de La Princesa, IIS-HUP, 28006 Madrid, Spain; (A.A.); (J.O.)
Jaime Pérez-Oteyza Hematology Department, Hospital Universitario HM Sanchinarro, 28050 Madrid, Spain;
Elena Ruiz Hematology Department, Hospital Universitario del Tajo, 28300 Madrid, Spain;
Eriel Alexis Marcheco-Pupo Hematology Department, Hospital Universitario Infanta Cristina, 28981 Madrid, Spain;
Ángel Cedillo Asociación Madrileña de Hematología y Hemoterapia (AMHH), 28010 Madrid, Spain;
Teresa de Soto Álvarez Hematology Department, Hospital Universitario La Paz, 28046 Madrid, Spain; (V.J.Y.); (T.d.S.Á.); (J.M.M.D.B.)
Patricia García Ramirez Hospital Universitario Príncipe de Asturias, Universidad de Alcalá, 28805 Madrid, Spain; (J.M.A.-C.); (P.G.R.); (J.G.-S.)
Rosalía Alonso Trillo Hematology Department, Hospital Universitario de Getafe, 28905 Madrid, Spain; (C.E.E.); (R.A.T.)
Pilar Herrera Hematology Department, Hospital Universitario Ramón Y Cajal, 28034 Madrid, Spain; (J.L.-J.); (P.H.)
María Luisa Bengochea Casado Hematology Department, Hospital Universitario Severo Ochoa, 28914 Madrid, Spain; (C.J.Y.); (M.L.B.C.)
Andrés Arroyo Barea Hematology Department, Hospital Universitario 12 de Octubre, imas12 Madrid, Universidad Complutense, CNIO-ISCIII, CIBERONC, 28041 Madrid, Spain; (R.G.-M.); (A.A.B.); (M.C.R.)
Jose Manuel Martin De Bustamante Hematology Department, Hospital Universitario La Paz, 28046 Madrid, Spain; (V.J.Y.); (T.d.S.Á.); (J.M.M.D.B.)
Javier Ortiz Hematology Department, Hospital Universitario de La Princesa, IIS-HUP, 28006 Madrid, Spain; (A.A.); (J.O.)
María Calbacho Robles Hematology Department, Hospital Universitario 12 de Octubre, imas12 Madrid, Universidad Complutense, CNIO-ISCIII, CIBERONC, 28041 Madrid, Spain; (R.G.-M.); (A.A.B.); (M.C.R.)
Julio García-Suárez Hospital Universitario Príncipe de Asturias, Universidad de Alcalá, 28805 Madrid, Spain; (J.M.A.-C.); (P.G.R.); (J.G.-S.)

Collapse